ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SLGL vs PYXS // EV/EBITDA & P/E VALUATION

Sol-Gel Technologies Ltd. (NASDAQ) VS. Pyxis Oncology Inc. (NASDAQ) • 15-METRIC TALLY: SLGL 5 — PYXS 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SLGL VS. PYXS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SLGL PYXS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 82.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield 0.12% — — TIE /fcf-yield <GO>
Operating Margin -38.90% -60.00% +21.10 SLGL /operating-margins <GO>
Net Profit Margin -31.60% -60.00% +28.40 SLGL /net-margins <GO>
Revenue Growth (YoY) 68.00% -14.20% +82.20 SLGL /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 8.54 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 3/9 +3.00 SLGL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.5 34.8 +6.71 SLGL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $224.8M $226.0M -$1.2M PYXS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SLGL REV PYXS REV SLGL GROSS % PYXS GROSS % SLGL FCF PYXS FCF
FY 2025 $19.4M $13.9M — 82.8% $275.0K -$63.5M
FY 2024 $11.5M $16.1M — 97.1% -$13.9M -$57.9M
FY 2023 $1.6M $0 — — -$17.7M -$70.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SLGL // BETA —
PYXS // BETA —